Hormonal Therapy of Polycystic Ovarian Syndrome Patients with Myo-Inositol & Metformin

Abstract

Objective: To see if Myo-Inositol and Metformin are comparable in terms of menstrual cycle frequency and mean LH/FSH in PCOS patients.

Study Design: Semi-Experimental

Study setting and duration: PAEC General Hospital, Islamabad, from 24th May to 24th November 2017 in the Department of Gynaecology and Obstetrics.

Materials and Procedures: There were 152 patients in the study, which was determined by using the WHO calculator. Two groups of patients were randomly assigned. Participant selection was based on non-probability sequential sampling. Metformin was given to the participants of Group B (the myoinositol group) every three days, while myoinositol was given to participants of Group A (myoinositol). After three months of drug therapy, the patients were contacted for a follow-up and all of their baseline measurements were retaken. After three months of treatment, LH/FSH levels and menstrual irregularities were compared to baseline levels. Post-segmentation, the t test and the chi-square test were used. The significance threshold was set at 0.05.

Results:The study included a total of 152 patients. The patients' median age was 27.4 years with a standard deviation of 7.6 years. Patients with polycystic ovary syndrome responded better to Myo-inositol than metformin in terms of the LH/FSH ratio (t=-5.89, p=0.000, C.I=95 percent) and menstrual cycle regularity (p=0.000).

Conclusion: Myo-Inositol was more effective than metformin at improving menstrual cycle regularity, lowering BMI, and lowering LH/FSH levels in women with polycystic ovary syndrome.